Laurence Albiges, MD

home / authors / laurence-albiges-md

Articles

Dr. Albiges on Next Steps for Immunotherapy in RCC

Dr. Albiges on Next Steps for Immunotherapy in RCC

Laurence Albiges, MD
August 18th 2017

Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses the next steps for immunotherapy for patients with renal cell carcinoma (RCC).

Read More

Dr. Albiges on Immunotherapy in Renal Cell Carcinoma

Dr. Albiges on Immunotherapy in Renal Cell Carcinoma

Laurence Albiges, MD
October 18th 2016

Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses how immunotherapy has had an impact on the field of renal cell carcinoma (RCC).

Read More

Dr. Albiges on Implementing mRCC Findings into Practice

Dr. Albiges on Implementing mRCC Findings into Practice

Laurence Albiges, MD
April 16th 2015

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses how oncologists can treat patients with metastatic renal cell carcinoma (mRCC) based off of findings from a study that looked at the impact of body mass index (BMI) on outcomes of these patients.

Read More

Dr. Albiges on the Impact of BMI on Outcomes of Patients With mRCC

Dr. Albiges on the Impact of BMI on Outcomes of Patients With mRCC

Laurence Albiges, MD
February 26th 2015

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need